The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines administered in the U.S. in ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.